Trial Profile
Phase II trial: efficacy and toxicity of induction pemetrexed (Alimta) and oxaliplatin (Eloxatin) in patients with locally advanced head and neck squamous cell carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Oxaliplatin (Primary) ; Pemetrexed (Primary)
- Indications Head and neck cancer
- Focus Biomarker; Therapeutic Use
- 09 Mar 2012 Actual patient number 42 added as reported by ClinicalTrials.gov.
- 09 Mar 2012 Actual end date Jun 2010 added as reported by ClinicalTrials.gov.
- 09 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.